Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoResponse

OncoResponse?uq=PEM9b6PF
2015 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$40M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 909 Fannin Street
  • Suite 2100
  • Houston, TX 77024
  • United States

+1 (206) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoResponse’s full profile, request a free trial.

OncoResponse Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 11-Sep-2018 $40M 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 23-Mar-2017 000.00 000.00 000.00 Completed Generating Revenue
1. Joint Venture 06-Oct-2015 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

OncoResponse Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

OncoResponse Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000000 07-Nov-2017 000000000000000000 Biotechnology 00000000 000000
To view this company’s complete investment and acquisition history, request access »

OncoResponse Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Qatar Investment Authority Sovereign Wealth Fund Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
Alexandria Real Estate Equities Real Estate Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

OncoResponse Executive Team (4)

Name Title Board
Seat
Contact
Info
Clifford Stocks Co-Founder, Chief Executive Officer & Board Member
Russ Hawkinson Chief Financial Officer
Anil Singhal Ph.D Chief Scientific Officer

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

OncoResponse Board Members (9)

Name Representing Role Since Contact
Info
Alan Ginsberg OncoResponse Board Member 000 0000
Andrew Perlman GreatPoint Ventures Board Member 000 0000
Clifford Stocks OncoResponse Co-Founder, Chief Executive Officer & Board Member 000 0000
John McKearn Ph.D RiverVest Venture Partners Board Member 000 0000
Nathan Jorgensen Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 9 board members. Get the full list »